UiPath Shares Surge. Is It Too Late to Buy the Stock?

UiPath reported fiscal Q3 revenue of $411 million, up 16% year‑over‑year and above the $392.9 million consensus, with adjusted EPS of $0.16 (vs. $0.15) and $59 million of new ARR; annualized renewal run rate rose 11% to $1.78 billion while dollar‑based net retention was 107% and gross retention 98%. Management emphasized early but accelerating momentum in AI agent orchestration (over 950 companies building agents, Maestro has orchestrated 365,000 processes) and a new ScreenpPlay offering, guided Q4 revenue of $462–467 million (midpoint above the $463.1M consensus) and ARR of $1.844–1.849 billion, finished the quarter with $1.5 billion cash and no debt, and trades at about 5.4x forward P/S (EV/forward-sales <4.5x).

Analysis

Market structure: UiPath (PATH) is positioned to capture the orchestration layer between low-cost RPA bots and expensive LLM agents, benefitting enterprise software integrators and AI-infrastructure suppliers (NVDA, MSFT, GOOGL) as demand for coordinated agent workflows rises. PATH’s 107% dollar-based net retention and +$59M new ARR this quarter signal expanding share within existing accounts, while pure-play LLM automation vendors and legacy RPA point-solutions face margin and pricing pressure as customers seek one orchestration stack.

Risk assessment: Key tail risks are regulatory constraints on data/agent liability, partner disintermediation (MSFT/GOOG/NVDA building native orchestration), and monetization failure of agents; a drop of DBNR below 100% or sequential new ARR < $40M would materially lower growth expectations. Near-term volatility (days–weeks) likely around guidance cadence; actionable evidence window is 1–3 quarters to prove agent monetization, and 2–5 years to capture TAM if adoption scales.

Trade implications: Tactical play is a size-limited long in PATH (scale-in 2–5% portfolio) with protective hedges; overweight NVDA/MSFT (1–3% each) to capture infra and ecosystem upside while underweight legacy application names. Options: prefer directional LEAP calls (12–24 months, target delta ~0.30) for asymmetric upside and buy 3–6 month 8–12% OTM puts as downside insurance if cost <3% of notional.

Contrarian angles: Consensus may underappreciate that RPA+LLM cost arbitration is a structural moat — if PATH converts agents to paid ARR at >$100/customer/year incrementally, upside is large; conversely, partners could internalize orchestration and compress PATH’s TAM. Watch for customer-level monetization metrics (agents per customer, revenue/agent) as the decisive datapoints; a miss vs. guidance midpoint (~$463M Q4 revenue) should be treated as a sell trigger.

Key Decisions for Investors

• Establish an initial 2–3% long position in PATH equity now; scale to 4–5% only if next-quarter ARR guidance clears the top-end ($1.849B) or sequential new ARR > $65M.
• Buy PATH 12–24 month LEAP calls targeting delta ~0.30 (allocate no more than 1–2% of capital) and simultaneously purchase 3–6 month 8–12% OTM puts as protection if put premium is <3% of notional.
• Overweight NVDA and MSFT by 1–3% each (vs. benchmark) to play GPU and cloud integration upside; take profits on a 25–40% move higher or if NVDA guidance indicates softened AI-cycle demand.
• Trigger-based risk control: trim or exit PATH if dollar-based net retention falls below 100% or quarterly new ARR prints < $40M or Q4 revenue guidance misses midpoint (~$463M) — these are objective sell signals to limit downside.